Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.

Medical science monitor : international medical journal of experimental and clinical research - 26 Jan 2016

He Yayi, Wang Yan, Boyle Theresa, Ren Shengxiang, Chan Dan, Rivard Chris, Li Xuefei, Li Jiayu, Zhou Caicun, Hirsch Fred R

Abstract excerpt

BACKGROUND: Hepatocyte growth factor (HGF)-mediated mesenchymal-to-epithelial transition factor (MET) gene amplification is a common mechanism for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). MET gene amplification has also been associated with hepatic metastases in patients with lung cancer. The aim of this study was to investigate whether hepatic metastases are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Liver Neoplasms

Share to Lung Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 26811313
DOI: 10.12659/msm.896607
PMCID: PMC4734673

Genes

EGFR
MET
HGF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.PMID 26811313Read ↗

Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma.Semantic proximity Read ↗

Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.Semantic proximity Read ↗

Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study.Semantic proximity Read ↗

Efficacy and safety of first-line EGFR-TKI combined with chemotherapy versus EGFR-TKI monotherapy in patients with EGFR-mutant non-small cell lung cancer and liver metastases: A propensity score-matched analysis.Semantic proximity Read ↗

Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.Semantic proximity Read ↗

Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis.Semantic proximity Read ↗

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients.Semantic proximity Read ↗

EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.Semantic proximity Read ↗

Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis.Semantic proximity Read ↗

Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study.Semantic proximity Read ↗

Prognosis of different bone metastases patterns in EGFR-mutant advanced lung adenocarcinoma patientsSemantic proximity Read ↗

Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.